Edgewise Therapeutics, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | — | $151.4M | $127.0M | $90.9M | $54.0M | $32.2M | $15.0M |
| SG&A Expense | — | $40.0M | $31.9M | $23.5M | $17.6M | $11.0M | $2.2M |
| Operating Income | — | $-191.4M | $-158.8M | $-114.4M | $-71.7M | $-43.2M | $-17.2M |
| Operating Margin | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | — | $-167.8M | $-133.8M | $-100.2M | — | — | — |
| Income Tax Expense | — | $4.0K | $3.0K | $4.0K | $0 | $0 | — |
| Net Income | — | $-167.8M | $-133.8M | $-100.2M | $-67.6M | $-42.8M | $-17.1M |
| Net Margin | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-1.63 | $-1.45 | $-1.57 | $-1.26 | $-1.14 | $-0.45 |
| EPS (Diluted) | — | $-1.63 | $-1.45 | $-1.57 | $-1.26 | $-1.14 | $-0.45 |
| Shares Outstanding (Basic) | 107.3M | 102.9M | 92.4M | 63.7M | 53.6M | 37.5M | 37.7M |
| Shares Outstanding (Diluted) | 107.3M | 102.9M | 92.4M | 63.7M | 53.6M | 37.5M | 37.7M |
| Dividends Per Share | — | — | — | — | — | — | — |